3 Nov: ECOG, Subgroups, & Unmet Need For Lung Cancer Awareness Month #LCAM I’m going to summarize 30 important lung cancer trials over 30 days. These posts are directed at non-medical professionals, with descriptions of the results and of what makes a good trial.1/12 #lcsm

4 Nov: Chemoradiation & patient selection For Lung Cancer Awareness Month #LCAM I’m going to summarize 30 important lung cancer trials over 30 days. These posts are directed at non-medical professionals, with descriptions of the results and of what makes a good trial.#lcsm 1/11

If a new treatment is a real advance, it does not require elaborate statistics to demonstrate its superiority. Overly complex analyses often reflect authors trying to make something out of nothing, or sponsors trying to design a trial more likely to lead to their desired result.

ecDNA are rogue genetic material that amplify genes, contribute to treatment resistance and drive genomic heterogeneity. We report on the Origins and impact of extrachromosomal DNA today in nature nature.com/articles/s4158…

What an amazing job by Dr. Mark Kris over the last decade+ to make the New York Lung meeting a real favorite for so many of us- 400+ attendees! What is Kris-tal clear is that Jamie and myself have huge shoes to fill but we will try our best- count on joining us in ‘25! That is

I wrote about the National Institutes of Health and the various serious and unserious proposals for NIH reform that have been floating around. It is important to understand how this agency actually functions and point criticism at the right problems. A short 🧵:

A warm welcome to Rockefeller, Avi! Avi Flamholz's lab will focus on the role of soil microbes in the carbon cycle, with the goal of unlocking new ways to harness the power of microbes to slow down or reverse rising global temperatures. rockefeller.edu/news/36919-new…

Patients and caregivers are no strangers to the plethora of costs associated with participating in an early phase cancer #clinicaltrial. Our study, published today in JCO Oncology Practice, affirms the significant #financialtoxicity experienced in this setting: ascopubs.org/doi/10.1200/OP…

Congratulations to Lindsay Caprio somnath tagore, many people in my group, and outstanding collaborators Denis Kresimir Bestak Fei Chen Lab Caris Life Sciences and many others on this paper, profiling non-small cell lung cancer brain metastases nature.com/articles/s4159…

Divarasib Looks to Best Sotorasib/Adagrasib and Solidify a Role in KRAS G12C-Mutated NSCLC Benjamin Herzberg Herbert Irving Comprehensive Cancer Center #oncology #NSCLC onclive.com/view/divarasib…

Daraxonrasib Generates Clinical Activity With Manageable Safety in RAS-Mutant NSCLC ESMO - Eur. Oncology #ELCC25 #lcsm #oncology onclive.com/view/daraxonra…

The research sector is exciting and busy with questions as investigators are exploring many approaches to inhibit KRAS, such as RAS(ON) and new allele-specific strategies in patients with #LungCancer and #PancreaticCancer. Benjamin Herzberg Herbert Irving Comprehensive Cancer Center hubs.li/Q03hdHQG0

This story is anecdotal - but even if only half-true, it's a worry. New drugs have given cancer (and other!) patients many, many years of extra life. Real harm can come from slow-downs and inexperienced hands. wsj.com/health/healthc…

For everyone interested in understanding human brain metastasis biology, check out this new collaborative paper with the Fan Bai lab. Congrats to Xudong and Jana Biermann, Ph.D. , and other members of my lab who have contributed.

It was a tremendous honor to receive this important Award on behalf of my laboratory. Thank you ASCI

Congrats, Neil! We will miss you at Columbia but happy for you! Great opportunity for your outstanding work.

#lcsm / #pathtwitter friends In the work-up of mediastinal masses - if you are smart, you do not forget about SMARCA4.. See below case-based overview of: ☑️differential dx guide ☑️path/molecular work up of novel entities ☑️biology/emerging treatment approaches Reading this

ICYMI: Herbert Irving Comprehensive Cancer Center fellow Michael May presented at #ASCO25 on our study on real-world eligibility for KRAS G12C #lungcancer trials that easing renal & CNS mets inclusion criteria does not compromise patient outcomes. Benjamin Herzberg Kathryn C. Arbour Dawn Hershman Jonathan W Lee

Drs. Noura Choudhury, MD & Marina Garassino have a great new paper out in The Lancet about the importance of the maintenance phase of treatment in extensive-stage small-cell lung cancer! You can read it at thelancet.com/journals/lance… #lungcancer #lungcancertreatment

Why do some genetic mutations devastate specific tissues while sparing others? We explore this question in GGC repeat disorders, revealing a mechanism linking protein aggregation to tRNA splicing failure in the brain. 🧵 on our new paper in Science: 🔗 science.org/doi/10.1126/sc…